Table of Contents Author Guidelines Submit a Manuscript
International Journal of Inflammation
Volume 2016 (2016), Article ID 1532832, 11 pages
http://dx.doi.org/10.1155/2016/1532832
Review Article

The Role of TLR2, TLR4, and TLR9 in the Pathogenesis of Atherosclerosis

Department of Anatomy, Faculty of Medicine and Surgery, University of Malta, Msida, Malta

Received 17 July 2016; Revised 5 September 2016; Accepted 15 September 2016

Academic Editor: Jean-Marc Cavaillon

Copyright © 2016 Mohsin H. K. Roshan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Libby, P. M. Ridker, and A. Maseri, “Inflammation and atherosclerosis,” Circulation, vol. 105, no. 9, pp. 1135–1143, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. C. A. Janeway Jr. and R. Medzhitov, “Innate immune recognition,” Annual Review of Immunology, vol. 20, no. 1, pp. 197–216, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. J. L. Witztum and A. H. Lichtman, “The influence of innate and adaptive immune responses on atherosclerosis,” Annual Review of Pathology: Mechanisms of Disease, vol. 9, pp. 73–102, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. O. Takeuchi and S. Akira, “Pattern recognition receptors and inflammation,” Cell, vol. 140, no. 6, pp. 805–820, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. B. Lemaitre, E. Nicolas, L. Michaut, J.-M. Reichhart, and J. A. Hoffmann, “The dorsoventral regulatory gene cassette spatzle/Toll/Cactus controls the potent antifungal response in Drosophila adults,” Cell, vol. 86, no. 6, pp. 973–983, 1996. View at Publisher · View at Google Scholar · View at Scopus
  6. R. Medzhitov, P. Preston-Hurlburt, and C. A. Janeway Jr., “A human homologue of the Drosophila Toll protein signals activation of adaptive immunity,” Nature, vol. 388, no. 6640, pp. 394–397, 1997. View at Publisher · View at Google Scholar · View at Scopus
  7. K. Hoshino, O. Takeuchi, T. Kawai et al., “Cutting edge: toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide evidence for TLR4 as the Lps gene product,” Journal of Immunology, vol. 162, no. 7, pp. 3749–3752, 1999. View at Google Scholar · View at Scopus
  8. T. Kawai and S. Akira, “The roles of TLRs, RLRs and NLRs in pathogen recognition,” International Immunology, vol. 21, no. 4, pp. 317–337, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. I. Botos, D. M. Segal, and D. R. Davies, “The structural biology of Toll-like receptors,” Structure, vol. 19, no. 4, pp. 447–459, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. N. Matsushima, T. Tanaka, P. Enkhbayar et al., “Comparative sequence analysis of leucine-rich repeats (LRRs) within vertebrate toll-like receptors,” BMC Genomics, vol. 8, article 124, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. X. H. Xu, P. K. Shah, E. Faure et al., “Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL,” Circulation, vol. 104, no. 25, pp. 3103–3108, 2001. View at Publisher · View at Google Scholar · View at Scopus
  12. J. E. Cole, E. Georgiou, and C. Monaco, “The expression and functions of toll-like receptors in atherosclerosis,” Mediators of Inflammation, vol. 2010, Article ID 393946, 18 pages, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. R. Ezzahiri, F. R. M. Stassen, H. R. M. Kurvers, V. Dolmans, P. J. E. H. M. Kitslaar, and C. A. Bruggeman, “Chlamydia pneumoniae infections augment atherosclerotic lesion formation: a role for serum amyloid P,” Acta Pathologica, Microbiologica, et Immunologica Scandinavica, vol. 114, no. 2, pp. 117–126, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. L. Törmäkangas, L. Erkkilä, T. Korhonen et al., “Effects of repeated Chlamydia pneumoniae inoculations on aortic lipid accumulation and inflammatory response in C57BL/6J mice,” Infection and Immunity, vol. 73, no. 10, pp. 6458–6466, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. E. Blessing, L. A. Campbell, M. E. Rosenfeld, N. Chough, and C.-C. Kuo, “Chlamydia pneumoniae infection accelerates hyperlipidemia induced atherosclerotic lesion development in C57BL/6J mice,” Atherosclerosis, vol. 158, no. 1, pp. 13–17, 2001. View at Publisher · View at Google Scholar · View at Scopus
  16. K. Aalto-Setälä, K. Laitinen, L. Erkkilä et al., “Chlamydia pneumoniae does not increase atherosclerosis in the aortic root of apolipoprotein E-deficient mice,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 21, no. 4, pp. 578–584, 2001. View at Publisher · View at Google Scholar · View at Scopus
  17. G. Caligiuri, M. Rottenberg, A. Nicoletti, H. Wigzell, and G. K. Hansson, “Chlamydia pneumoniae infection does not induce or modify atherosclerosis in mice,” Circulation, vol. 103, no. 23, pp. 2834–2838, 2001. View at Publisher · View at Google Scholar · View at Scopus
  18. J. Millán, X. Pintó, A. Muñoz et al., “Lipoprotein ratios: physiological significance and clinical usefulness in cardiovascular prevention,” Vascular Health and Risk Management, vol. 5, pp. 757–765, 2009. View at Google Scholar · View at Scopus
  19. N. J. Stone, J. G. Robinson, A. H. Lichtenstein et al., “2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,” Journal of the American College of Cardiology, vol. 63, no. 25, pp. 2889–2934, 2014. View at Publisher · View at Google Scholar
  20. S. Garrido-Urbani, M. Meguenani, F. Montecucco, and B. A. Imhof, “Immunological aspects of atherosclerosis,” Seminars in Immunopathology, vol. 36, no. 1, pp. 73–91, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. I. Levitan, S. Volkov, and P. V. Subbaiah, “Oxidized LDL: diversity, patterns of recognition, and pathophysiology,” Antioxidants and Redox Signaling, vol. 13, no. 1, pp. 39–75, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. M. F. Khalil, W. D. Wagner, and I. J. Goldberg, “Molecular interactions leading to lipoprotein retention and the initiation of atherosclerosis,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 12, pp. 2211–2218, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. P. Libby, “Changing concepts of atherogenesis,” Journal of Internal Medicine, vol. 247, no. 3, pp. 349–358, 2000. View at Publisher · View at Google Scholar · View at Scopus
  24. G. K. Hansson, “Immune mechanisms in atherosclerosis,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 21, no. 12, pp. 1876–1890, 2001. View at Publisher · View at Google Scholar
  25. H. C. Stary, A. B. Chandler, S. Glagov et al., “A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association,” Circulation, vol. 89, no. 5, pp. 2462–2478, 1994. View at Publisher · View at Google Scholar
  26. H. C. Stary, A. B. Chandler, R. E. Dinsmore et al., “A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the committee on vascular lesions of the council on arteriosclerosis, American Heart Association,” Circulation, vol. 92, no. 5, pp. 1355–1374, 1995. View at Publisher · View at Google Scholar · View at Scopus
  27. A. J. Lusis, “Atherosclerosis,” Nature, vol. 407, no. 6801, pp. 233–241, 2000. View at Publisher · View at Google Scholar · View at Scopus
  28. W.-S. Lee, M. K. Jain, B. M. Arkonac et al., “Thy-1, a novel marker for angiogenesis upregulated by inflammatory cytokines,” Circulation Research, vol. 82, no. 8, pp. 845–851, 1998. View at Publisher · View at Google Scholar · View at Scopus
  29. P. R. Moreno, K. R. Purushothaman, E. Zias, J. Sanz, and V. Fuster, “Neovascularization in human atherosclerosis,” Current Molecular Medicine, vol. 6, no. 5, pp. 457–477, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. V. Fuster, P. R. Moreno, Z. A. Fayad, R. Corti, and J. J. Badimon, “Atherothrombosis and high-risk plaque: part I: evolving concepts,” Journal of the American College of Cardiology, vol. 46, no. 6, pp. 937–954, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Nichols, N. Townsend, P. Scarborough, and M. Rayner, “Cardiovascular disease in Europe 2014: epidemiological update,” European Heart Journal, vol. 35, no. 42, pp. 2950–2959, 2014. View at Publisher · View at Google Scholar · View at Scopus
  32. K. S. Reddy, “Cardiovascular disease in non-Western countries,” The New England Journal of Medicine, vol. 350, no. 24, pp. 2438–2440, 2004. View at Publisher · View at Google Scholar · View at Scopus
  33. J. A. Finegold, P. Asaria, and D. P. Francis, “Mortality from ischaemic heart disease by country, region, and age: statistics from World Health Organisation and United Nations,” International Journal of Cardiology, vol. 168, no. 2, pp. 934–945, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. K. Takeda and S. Akira, “TLR signaling pathways,” Seminars in Immunology, vol. 16, no. 1, pp. 3–9, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. J. Gohda, T. Matsumura, and J.-I. Inoue, “Cutting edge: TNFR-associated factor (TRAF) 6 is essential for MyD88-dependent pathway but not Toll/IL-1 receptor domain-containing adaptor-inducing IFN-β (TRIF)-dependent pathway in TLR signaling,” Journal of Immunology, vol. 173, no. 5, pp. 2913–2917, 2004. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Muzio, J. Ni, P. Feng, and V. M. Dixit, “IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling,” Science, vol. 278, no. 5343, pp. 1612–1615, 1997. View at Publisher · View at Google Scholar · View at Scopus
  37. Z. J. Chen, “Ubiquitin signalling in the NF-κB pathway,” Nature Cell Biology, vol. 7, no. 8, pp. 758–765, 2005. View at Publisher · View at Google Scholar
  38. C. Wang, L. Deng, M. Hong, G. R. Akkaraju, J.-I. Inoue, and Z. J. Chen, “TAK1 is a ubiquitin-dependent kinase of MKK and IKK,” Nature, vol. 412, no. 6844, pp. 346–351, 2001. View at Publisher · View at Google Scholar · View at Scopus
  39. S. Ghosh, M. J. May, and E. B. Kopp, “NF-κB and rel proteins: evolutionarily conserved mediators of immune responses,” Annual Review of Immunology, vol. 16, pp. 225–260, 1998. View at Publisher · View at Google Scholar · View at Scopus
  40. T. Kawasaki and T. Kawai, “Toll-like receptor signaling pathways,” Frontiers in Immunology, vol. 5, article 461, 2014. View at Publisher · View at Google Scholar
  41. M. Yamamoto, S. Sato, H. Hemmi et al., “Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway,” Science, vol. 301, no. 5633, pp. 640–643, 2003. View at Publisher · View at Google Scholar · View at Scopus
  42. S. Uematsu and S. Akira, “Toll-like receptors and type I Interferons,” The Journal of Biological Chemistry, vol. 282, no. 21, pp. 15319–15324, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. S. J. Noppert, K. A. Fitzgerald, and P. J. Hertzog, “The role of type I interferons in TLR responses,” Immunology and Cell Biology, vol. 85, no. 6, pp. 446–457, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. C. Wang, T. Chen, J. Zhang et al., “The E3 ubiquitin ligase Nrdp1 ‘preferentially’ promotes TLR-mediated production of type I interferon,” Nature Immunology, vol. 10, no. 7, pp. 744–752, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. X. Liu, Z. Zhan, D. Li et al., “Intracellular MHC class II molecules promote TLR-triggered innate immune responses by maintaining activation of the kinase Btk,” Nature Immunology, vol. 12, no. 5, pp. 416–424, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. A. O. Aliprantis, R.-B. Yang, M. R. Mark et al., “Cell activation and apoptosis by bacterial lipoproteins through Toll- like receptor-2,” Science, vol. 285, no. 5428, pp. 736–739, 1999. View at Publisher · View at Google Scholar · View at Scopus
  47. A. O. Aliprantis, R.-B. Yang, D. S. Weiss, P. Godowski, and A. Zychlinsky, “The apoptotic signaling pathway activated by Toll-like receptor-2,” The EMBO Journal, vol. 19, no. 13, pp. 3325–3336, 2000. View at Publisher · View at Google Scholar · View at Scopus
  48. A. Ashkenazi and V. M. Dixit, “Death receptors: signaling and modulation,” Science, vol. 281, no. 5381, pp. 1305–1308, 1998. View at Publisher · View at Google Scholar · View at Scopus
  49. L. Yu, L. Wang, and S. Chen, “Endogenous toll-like receptor ligands and their biological significance,” Journal of Cellular and Molecular Medicine, vol. 14, no. 11, pp. 2592–2603, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. A. M. Piccinini and K. S. Midwood, “DAMPening inflammation by modulating TLR signalling,” Mediators of Inflammation, vol. 2010, Article ID 672395, 21 pages, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. Y. Okamura, M. Watari, E. S. Jerud et al., “The extra domain A of fibronectin activates toll-like receptor 4,” The Journal of Biological Chemistry, vol. 276, no. 13, pp. 10229–10233, 2001. View at Publisher · View at Google Scholar · View at Scopus
  52. S. T. Smiley, J. A. King, and W. W. Hancock, “Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4,” Journal of Immunology, vol. 167, no. 5, pp. 2887–2894, 2001. View at Publisher · View at Google Scholar · View at Scopus
  53. K. R. Taylor, K. Yamasaki, K. A. Radek et al., “Recognition of hyaluronan released in sterile injury involves a unique receptor complex dependent on toll-like receptor 4, CD44, and MD-2,” The Journal of Biological Chemistry, vol. 282, no. 25, pp. 18265–18275, 2007. View at Publisher · View at Google Scholar · View at Scopus
  54. R. M. Vabulas, P. Ahmad-Nejad, C. Da Costa et al., “Endocytosed HSP60s use toll-like receptor 2 (TLR2) and TLR4 to activate the toll/interleukin-1 receptor signaling pathway in innate immune cells,” Journal of Biological Chemistry, vol. 276, no. 33, pp. 31332–31339, 2001. View at Publisher · View at Google Scholar · View at Scopus
  55. Y. S. Bae, J. H. Lee, S. H. Choi et al., “Macrophages generate reactive oxygen species in response to minimally oxidized low-density lipoprotein: toll-like receptor 4- and spleen tyrosine kinase-dependent activation of NADPH oxidase 2,” Circulation Research, vol. 104, no. 2, pp. 210–218, 2009. View at Publisher · View at Google Scholar · View at Scopus
  56. K. Ohashi, V. Burkart, S. Flohé, and H. Kolb, “Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex,” Journal of Immunology, vol. 164, no. 2, pp. 558–561, 2000. View at Publisher · View at Google Scholar · View at Scopus
  57. Y. Bulut, E. Faure, L. Thomas et al., “Chlamydial heat shock protein 60 activates macrophages and endothelial cells through toll-like receptor 4 and MD2 in a MyD88-dependent pathway,” The Journal of Immunology, vol. 168, no. 3, pp. 1435–1440, 2002. View at Publisher · View at Google Scholar · View at Scopus
  58. C. U. Prazeres da Costa, N. Wantia, C. J. Kirschning et al., “Heat shock protein 60 from Chlamydia pneumoniae elicits an unusual set of imflammatory responses via Tol-like receptor 2 and 4 in vivo,” European Journal of Immunology, vol. 34, no. 10, pp. 2874–2884, 2004. View at Publisher · View at Google Scholar · View at Scopus
  59. B. Gao and M.-F. Tsan, “Endotoxin contamination in recombinant human heat shock protein 70 (Hsp70) preparation is responsible for the induction of tumor necrosis factor α release by murine macrophages,” The Journal of Biological Chemistry, vol. 278, no. 1, pp. 174–179, 2003. View at Publisher · View at Google Scholar · View at Scopus
  60. M.-F. Tsan and B. Gao, “Endogenous ligands of Toll-like receptors,” Journal of Leukocyte Biology, vol. 76, no. 3, pp. 514–519, 2004. View at Publisher · View at Google Scholar · View at Scopus
  61. U. Zähringer, B. Lindner, S. Inamura, H. Heine, and C. Alexander, “TLR2—promiscuous or specific? A critical re-evaluation of a receptor expressing apparent broad specificity,” Immunobiology, vol. 213, no. 3-4, pp. 205–224, 2008. View at Publisher · View at Google Scholar · View at Scopus
  62. T. H. Flo, Ø. Halaas, S. Torp et al., “Differential expression of toll-like receptor 2 in human cells,” Journal of Leukocyte Biology, vol. 69, no. 3, pp. 474–481, 2001. View at Google Scholar · View at Scopus
  63. L. Oliveira-Nascimento, P. Massari, and L. M. Wetzler, “The role of TLR2 in infection and immunity,” Frontiers in Immunology, vol. 3, article 79, 2012. View at Publisher · View at Google Scholar
  64. K. Edfeldt, J. Swedenborg, G. K. Hansson, and Z.-Q. Yan, “Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation,” Circulation, vol. 105, no. 10, pp. 1158–1161, 2002. View at Google Scholar · View at Scopus
  65. S. Dunzendorfer, H.-K. Lee, and P. S. Tobias, “Flow-dependent regulation of endothelial toll-like receptor 2 expression through inhibition of SP1 activity,” Circulation Research, vol. 95, no. 7, pp. 684–691, 2004. View at Publisher · View at Google Scholar · View at Scopus
  66. A. E. Mullick, P. S. Tobias, and L. K. Curtiss, “Modulation of atherosclerosis in mice by Toll-like receptor 2,” The Journal of Clinical Investigation, vol. 115, no. 11, pp. 3149–3156, 2005. View at Publisher · View at Google Scholar · View at Scopus
  67. A. E. Mullick, K. Soldau, W. B. Kiosses, T. A. Bell III, P. S. Tobias, and L. K. Curtiss, “Increased endothelial expression of Toll-like receptor 2 at sites of disturbed blood flow exacerbates early atherogenic events,” Journal of Experimental Medicine, vol. 205, no. 2, pp. 373–383, 2008. View at Publisher · View at Google Scholar · View at Scopus
  68. A. H. Schoneveld, M. M. Oude Nijhuis, B. Van Middelaar, J. D. Laman, D. P. V. De Kleijn, and G. Pasterkamp, “Toll-like receptor 2 stimulation induces intimal hyperplasia and atherosclerotic lesion development,” Cardiovascular Research, vol. 66, no. 1, pp. 162–169, 2005. View at Publisher · View at Google Scholar · View at Scopus
  69. G.-L. Lee, Y.-W. Chang, J.-Y. Wu et al., “TLR 2 induces vascular smooth muscle cell migration through cAMP response element-binding protein-mediated interleukin-6 production,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 32, no. 11, pp. 2751–2760, 2012. View at Publisher · View at Google Scholar · View at Scopus
  70. M. Madan and S. Amar, “Toll-like receptor-2 mediates diet and/or pathogen associated atherosclerosis: proteomic findings,” PLoS ONE, vol. 3, no. 9, Article ID e3204, 2008. View at Publisher · View at Google Scholar · View at Scopus
  71. T. Shishido, N. Nozaki, H. Takahashi et al., “Central role of endogenous Toll-like receptor-2 activation in regulating inflammation, reactive oxygen species production, and subsequent neointimal formation after vascular injury,” Biochemical and Biophysical Research Communications, vol. 345, no. 4, pp. 1446–1453, 2006. View at Publisher · View at Google Scholar · View at Scopus
  72. J. Favre, P. Musette, V. Douin-Echinard et al., “Toll-like receptors 2-deficient mice are protected against postischemic coronary endothelial dysfunction,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 5, pp. 1064–1071, 2007. View at Publisher · View at Google Scholar · View at Scopus
  73. L. Chávez-Sánchez, M. G. Garza-Reyes, J. E. Espinosa-Luna, K. Chávez-Rueda, M. V. Legorreta-Haquet, and F. Blanco-Favela, “The role of TLR2, TLR4 and CD36 in macrophage activation and foam cell formation in response to oxLDL in humans,” Human Immunology, vol. 75, no. 4, pp. 322–329, 2014. View at Publisher · View at Google Scholar · View at Scopus
  74. K. Inoue, K.-I. Kawahara, K. K. Biswas et al., “HMGB1 expression by activated vascular smooth muscle cells in advanced human atherosclerosis plaques,” Cardiovascular Pathology, vol. 16, no. 3, pp. 136–143, 2007. View at Publisher · View at Google Scholar · View at Scopus
  75. D. Messmer, H. Yang, G. Telusma et al., “High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization,” The Journal of Immunology, vol. 173, no. 1, pp. 307–313, 2004. View at Publisher · View at Google Scholar · View at Scopus
  76. M. A. Christman II, D. J. Goetz, E. Dickerson et al., “Wnt5a is expressed in murine and human atherosclerotic lesions,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 294, no. 6, pp. H2864–H2870, 2008. View at Publisher · View at Google Scholar · View at Scopus
  77. P. M. Bhatt, C. J. Lewis, D. L. House et al., “Increased Wnt5a mRNA expression in advanced atherosclerotic lesions, and oxidized LDL treated human monocyte-derived macrophages,” The Open Circulation and Vascular Journal, vol. 5, no. 1, pp. 1–7, 2012. View at Publisher · View at Google Scholar
  78. L. Qin, R. Hu, N. Zhu et al., “The novel role and underlying mechanism of Wnt5a in regulating cellular cholesterol accumulation,” Clinical and Experimental Pharmacology and Physiology, vol. 41, no. 9, pp. 671–678, 2014. View at Publisher · View at Google Scholar · View at Scopus
  79. I. Ackers, C. Szymanski, K. J. Duckett, K. McCall, and R. Malgor, “Wnt5a signaling in atherosclerosis, its effect on OxLDL uptake and foam cell differentiation,” The FASEB Journal, vol. 29, supplement 1, p. 609.4, 2015. View at Google Scholar
  80. P. M. Bhatt and R. Malgor, “Wnt5a: a player in the pathogenesis of atherosclerosis and other inflammatory disorders,” Atherosclerosis, vol. 237, no. 1, pp. 155–162, 2014. View at Publisher · View at Google Scholar · View at Scopus
  81. N. J. Gay, M. F. Symmons, M. Gangloff, and C. E. Bryant, “Assembly and localization of Toll-like receptor signalling complexes,” Nature Reviews Immunology, vol. 14, no. 8, pp. 546–558, 2014. View at Publisher · View at Google Scholar · View at Scopus
  82. H. Methe, J.-O. Kim, S. Kofler, M. Weis, M. Nabauer, and J. Koglin, “Expansion of circulating toll-like receptor 4-positive monocytes in patients with acute coronary syndrome,” Circulation, vol. 111, no. 20, pp. 2654–2661, 2005. View at Publisher · View at Google Scholar · View at Scopus
  83. H.-L. Geng, H.-Q. Lu, L.-Z. Zhang et al., “Increased expression of Toll like receptor 4 on peripheral-blood mononuclear cells in patients with coronary arteriosclerosis disease,” Clinical and Experimental Immunology, vol. 143, no. 2, pp. 269–273, 2006. View at Publisher · View at Google Scholar · View at Scopus
  84. M. Satoh, Y. Shimoda, C. Maesawa et al., “Activated toll-like receptor 4 in monocytes is associated with heart failure after acute myocardial infarction,” International Journal of Cardiology, vol. 109, no. 2, pp. 226–234, 2006. View at Publisher · View at Google Scholar · View at Scopus
  85. L. D. Tapp, E. Shantsila, B. J. Wrigley, S. Montoro-Garcia, and G. Y. H. Lip, “TLR4 expression on monocyte subsets in myocardial infarction,” Journal of Internal Medicine, vol. 273, no. 3, pp. 294–305, 2013. View at Publisher · View at Google Scholar · View at Scopus
  86. K. W. Howell, X. Meng, D. A. Fullerton, C. Jin, T. B. Reece, and J. C. Cleveland Jr., “Toll-like receptor 4 mediates oxidized LDL-induced macrophage differentiation to foam cells,” Journal of Surgical Research, vol. 171, no. 1, pp. e27–e31, 2011. View at Publisher · View at Google Scholar · View at Scopus
  87. K. Yang, X. J. Zhang, L. J. Cao et al., “Toll-like receptor 4 mediates inflammatory cytokine secretion in smooth muscle cells induced by oxidized low-density lipoprotein,” PLoS ONE, vol. 9, no. 4, Article ID e95935, 2014. View at Publisher · View at Google Scholar · View at Scopus
  88. Y. I. Miller, S. Viriyakosol, C. J. Binder, J. R. Feramisco, T. N. Kirkland, and J. L. Witztum, “Minimally modified LDL binds to CD14, induces macrophage spreading via TLR4/MD-2, and inhibits phagocytosis of apoptotic cells,” The Journal of Biological Chemistry, vol. 278, no. 3, pp. 1561–1568, 2003. View at Publisher · View at Google Scholar · View at Scopus
  89. S.-H. Choi, R. Harkewicz, J. H. Lee et al., “Lipoprotein accumulation in macrophages via toll-like receptor-4-dependent fluid phase uptake,” Circulation Research, vol. 104, no. 12, pp. 1355–1363, 2009. View at Publisher · View at Google Scholar · View at Scopus
  90. Y. I. Miller, S.-H. Choi, P. Wiesner, and Y. S. Bae, “The SYK side of TLR4: signalling mechanisms in response to LPS and minimally oxidized LDL,” British Journal of Pharmacology, vol. 167, no. 5, pp. 990–999, 2012. View at Publisher · View at Google Scholar · View at Scopus
  91. H. Björkbacka, V. V. Kunjathoor, K. J. Moore et al., “Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways,” Nature Medicine, vol. 10, no. 4, pp. 416–421, 2004. View at Publisher · View at Google Scholar · View at Scopus
  92. K. S. Michelsen, M. H. Wong, P. K. Shah et al., “Lack of toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 29, pp. 10679–10684, 2004. View at Publisher · View at Google Scholar · View at Scopus
  93. M. Higashimori, J. B. Tatro, K. J. Moore, M. E. Mendelsohn, J. B. Galper, and D. Beasley, “Role of toll-like receptor 4 in intimal foam cell accumulation in apolipoprotein E-deficient mice,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 31, no. 1, pp. 50–57, 2011. View at Publisher · View at Google Scholar · View at Scopus
  94. K. R. Coenen, M. L. Gruen, R. S. Lee-Young, M. J. Puglisi, D. H. Wasserman, and A. H. Hasty, “Impact of macrophage toll-like receptor 4 deficiency on macrophage infiltration into adipose tissue and the artery wall in mice,” Diabetologia, vol. 52, no. 2, pp. 318–328, 2009. View at Publisher · View at Google Scholar · View at Scopus
  95. G. Pasterkamp, A. H. Schoneveld, D. J. Hijnen et al., “Atherosclerotic arterial remodeling and the localization of macrophages and matrix metalloproteases 1, 2 and 9 in the human coronary artery,” Atherosclerosis, vol. 150, no. 2, pp. 245–253, 2000. View at Publisher · View at Google Scholar · View at Scopus
  96. S. C. G. Hollestelle, M. R. De Vries, J. K. Van Keulen et al., “Toll-like receptor 4 is involved in outward arterial remodeling,” Circulation, vol. 109, no. 3, pp. 393–398, 2004. View at Publisher · View at Google Scholar
  97. Y. Ishikawa, M. Satoh, T. Itoh, Y. Minami, Y. Takahashi, and M. Akamura, “Local expression of Toll-like receptor 4 at the site of ruptured plaques in patients with acute myocardial infarction,” Clinical Science, vol. 115, no. 3-4, pp. 133–140, 2008. View at Publisher · View at Google Scholar · View at Scopus
  98. S. Gargiulo, P. Gamba, G. Testa et al., “Relation between TLR4/NF-κB signaling pathway activation by 27-hydroxycholesterol and 4-hydroxynonenal, and atherosclerotic plaque instability,” Aging Cell, vol. 14, no. 4, pp. 569–581, 2015. View at Publisher · View at Google Scholar · View at Scopus
  99. E. W. Raines, “The extracellular matrix can regulate vascular cell migration, proliferation, and survival: relationships to vascular disease,” International Journal of Experimental Pathology, vol. 81, no. 3, pp. 173–182, 2000. View at Google Scholar · View at Scopus
  100. A. W. Orr, J. M. Sanders, M. Bevard, E. Coleman, I. J. Sarembock, and M. A. Schwartz, “The subendothelial extracellular matrix modulates NF-κB activation by flow: a potential role in atherosclerosis,” The Journal of Cell Biology, vol. 169, no. 1, pp. 191–202, 2005. View at Publisher · View at Google Scholar · View at Scopus
  101. B. V. Shekhonin, S. P. Domogatsky, G. L. Idelson, V. E. Koteliansky, and V. S. Rukosuev, “Relative distribution of fibronectin and type I, III, IV, V collagens in normal and atherosclerotic intima of human arteries,” Atherosclerosis, vol. 67, no. 1, pp. 9–16, 1987. View at Publisher · View at Google Scholar · View at Scopus
  102. E. S. White, F. E. Baralle, and A. F. Muro, “New insights into form and function of fibronectin splice variants,” Journal of Pathology, vol. 216, no. 1, pp. 1–14, 2008. View at Publisher · View at Google Scholar · View at Scopus
  103. M. H. Tan, Z. Sun, S. L. Opitz, T. E. Schmidt, J. H. Peters, and E. L. George, “Deletion of the alternatively spliced fibronectin EIIIA domain in mice reduces atherosclerosis,” Blood, vol. 104, no. 1, pp. 11–18, 2004. View at Publisher · View at Google Scholar · View at Scopus
  104. V. R. Babaev, F. Porro, M. F. Linton, S. Fazio, F. E. Baralle, and A. F. Muro, “Absence of regulated splicing of fibronectin EDA exon reduces atherosclerosis in mice,” Atherosclerosis, vol. 197, no. 2, pp. 534–540, 2008. View at Publisher · View at Google Scholar · View at Scopus
  105. P. Doddapattar, C. Gandhi, P. Prakash et al., “Fibronectin splicing variants containing extra domain A promote atherosclerosis in mice through Toll-like receptor 4,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 35, no. 11, pp. 2391–2400, 2015. View at Publisher · View at Google Scholar · View at Scopus
  106. P. Prakash, P. P. Kulkarni, S. R. Lentz, and A. K. Chauhan, “Cellular fibronectin containing extra domain A promotes arterial thrombosis in mice through platelet Toll-like receptor 4,” Blood, vol. 125, no. 20, pp. 3164–3172, 2015. View at Publisher · View at Google Scholar
  107. H. Hemmi, O. Takeuchi, T. Kawai et al., “A Toll-like receptor recognizes bacterial DNA,” Nature, vol. 408, no. 6813, pp. 740–745, 2000. View at Publisher · View at Google Scholar · View at Scopus
  108. A. Dalpke, J. Frank, M. Peter, and K. Heeg, “Activation of toll-like receptor 9 by DNA from different bacterial species,” Infection and Immunity, vol. 74, no. 2, pp. 940–946, 2006. View at Publisher · View at Google Scholar · View at Scopus
  109. R. Sorrentino, S. Morello, S. Chen, E. Bonavita, and A. Pinto, “The activation of liver X receptors inhibits toll-like receptor-9-induced foam cell formation,” Journal of Cellular Physiology, vol. 223, no. 1, pp. 158–167, 2010. View at Publisher · View at Google Scholar · View at Scopus
  110. M. Baranowski, “Biological role of liver X receptors,” Journal of Physiology and Pharmacology, vol. 59, supplement 7, pp. 31–55, 2008. View at Google Scholar
  111. A. Niessner, K. Sato, E. L. Chaikof, I. Colmegna, J. J. Goronzy, and C. M. Weyand, “Pathogen-sensing plasmacytoid dendritic cells stimulate cytotoxic T-cell function in the atherosclerotic plaque through interferon-α,” Circulation, vol. 114, no. 23, pp. 2482–2489, 2006. View at Publisher · View at Google Scholar · View at Scopus
  112. J.-D. Bouaziz, S. Calbo, M. Maho-Vaillant et al., “IL-10 produced by activated human B cells regulates CD4+ T-cell activation in vitro,” European Journal of Immunology, vol. 40, no. 10, pp. 2686–2691, 2010. View at Publisher · View at Google Scholar · View at Scopus
  113. Z. Waibler, M. Anzaghe, A. Konur, S. Akira, W. Müller, and U. Kalinke, “Excessive CpG 1668 stimulation triggers IL-10 production by cDC that inhibits IFN-α responses by pDC,” European Journal of Immunology, vol. 38, no. 11, pp. 3127–3137, 2008. View at Publisher · View at Google Scholar · View at Scopus
  114. C. Koulis, Y.-C. Chen, C. Hausding et al., “Protective role for toll-like receptor-9 in the development of atherosclerosis in apolipoprotein E–deficient mice,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 34, no. 3, pp. 516–525, 2014. View at Publisher · View at Google Scholar · View at Scopus
  115. C. Ma, Q. Ouyang, Z. Huang et al., “Toll-like receptor 9 inactivation alleviated atherosclerotic progression and inhibited macrophage polarized to M1 phenotype in ApoE−/− mice,” Disease Markers, vol. 2015, Article ID 909572, 9 pages, 2015. View at Publisher · View at Google Scholar
  116. A. O. Krogmann, E. Lüsebrink, M. Steinmetz et al., “Proinflammatory stimulation of toll-like receptor 9 with high dose CpG ODN 1826 impairs endothelial regeneration and promotes atherosclerosis in mice,” PLoS ONE, vol. 11, no. 1, article e0146326, 2016. View at Publisher · View at Google Scholar · View at Scopus
  117. H. Ait-Oufella, B. L. Salomon, S. Potteaux et al., “Natural regulatory T cells control the development of atherosclerosis in mice,” Nature Medicine, vol. 12, no. 2, pp. 178–180, 2006. View at Publisher · View at Google Scholar · View at Scopus
  118. C. Buono, C. J. Binder, G. Stavrakis, J. L. Witztum, L. H. Glimcher, and A. H. Lichtman, “T-bet deficiency reduces atherosclerosis and alters plaque antigen-specific immune responses,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 5, pp. 1596–1601, 2005. View at Publisher · View at Google Scholar · View at Scopus
  119. K. Tse, H. Tse, J. Sidney, A. Sette, and K. Ley, “T cells in atherosclerosis,” International Immunology, vol. 25, no. 11, pp. 615–622, 2013. View at Publisher · View at Google Scholar · View at Scopus
  120. A. C. Foks, A. H. Lichtman, and J. Kuiper, “Treating atherosclerosis with regulatory T cells,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 35, no. 2, pp. 280–287, 2015. View at Google Scholar
  121. M. Subramanian, E. Thorp, G. K. Hansson, and I. Tabas, “Treg-mediated suppression of atherosclerosis requires MYD88 signaling in DCs,” The Journal of Clinical Investigation, vol. 123, no. 1, pp. 179–188, 2013. View at Publisher · View at Google Scholar · View at Scopus
  122. B. Hou, B. Reizis, and A. L. DeFranco, “Toll-like receptors activate innate and adaptive immunity by using dendritic cell-intrinsic and -extrinsic mechanisms,” Immunity, vol. 29, no. 2, pp. 272–282, 2008. View at Publisher · View at Google Scholar · View at Scopus
  123. G. K. Hansson and J. Nilsson, “Vaccination against atherosclerosis? Induction of atheroprotective immunity,” Seminars in Immunopathology, vol. 31, no. 1, pp. 95–101, 2009. View at Publisher · View at Google Scholar · View at Scopus
  124. S. Kiechl, E. Lorenz, M. Reindl et al., “Toll-like receptor 4 polymorphisms and atherogenesis,” The New England Journal of Medicine, vol. 347, no. 3, pp. 185–192, 2002. View at Publisher · View at Google Scholar · View at Scopus
  125. R. Labrum, S. Bevan, M. Sitzer, M. Lorenz, and H. S. Markus, “Toll receptor polymorphisms and carotid artery intima-media thickness,” Stroke, vol. 38, no. 4, pp. 1179–1184, 2007. View at Publisher · View at Google Scholar · View at Scopus
  126. N. Ameziane, T. Beillat, P. Verpillat et al., “Association of the Toll-like receptor 4 gene Asp299Gly polymorphism with acute coronary events,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 12, pp. e61–e64, 2003. View at Publisher · View at Google Scholar
  127. S. M. Boekholdt, W. R. P. Agema, R. J. G. Peters et al., “Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events,” Circulation, vol. 107, no. 19, pp. 2416–2421, 2003. View at Publisher · View at Google Scholar · View at Scopus
  128. W. Koch, P. Hoppmann, A. Pfeufer, A. Schömig, and A. Kastrati, “Toll-like receptor 4 gene polymorphisms and myocardial infarction: no association in a Caucasian population,” European Heart Journal, vol. 27, no. 21, pp. 2524–2529, 2006. View at Publisher · View at Google Scholar · View at Scopus
  129. A. G. Kutikhin, A. V. Ponasenko, M. V. Khutornaya et al., “Association of TLR and TREM-1 gene polymorphisms with atherosclerosis severity in a Russian population,” Meta Gene, vol. 9, pp. 76–89, 2016. View at Google Scholar
  130. T. Tahara, T. Arisawa, T. Shibata, I. Hirata, and H. Nakano, “Absence of common polymorphisms of toll like receptor 4 (TLR4): Asp299Gly, Thr399Ile in patients with gastroduodenal diseases in Japan,” Journal of Clinical Biochemistry and Nutrition, vol. 40, no. 1, pp. 62–65, 2007. View at Publisher · View at Google Scholar · View at Scopus